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Abstract 
One of the most important consequences of chronically active ulcerative colitis 
(UC) or Crohn’s disease (CD) – the two major forms of inflammatory bowel disease 
(IBD) - is the development of colorectal cancer (CRC). An increased risk for the 
occurrence of CRC in up to 30% of affected patients after 35 years of UC has been 
reported. Recent evidence from population based studies indicates a lower risk. 
Nevertheless the incidence is still significantly increased as compared to individuals 
without chronic colitis. Colitis-associated CRC (CAC) does not display the adenoma-
carcinoma sequence which is typical for sporadic CRC and the pathophysiology 
appears to be different. Chronic inflammation and the increased turnover of 
epithelial cells contribute to the development of low- and high-grade dysplasia 
which may further transform into CAC. Reactive oxygen species (ROS) generated by 
the inflammatory infiltrate are thought to contribute to the generation of dysplastic 
lesions. In sporadic CRC the sequence of mutations that finally lead to malignancy 
involves early activation of Wnt/β-catenin pathway (in 90 % of cases) including 
mutations in adenomatous polyposis coli (APC) tumor suppressor gene, its 
regulating kinase GSK3β and β-catenin itself. β-catenin mutations are rarer in CAC 
and mutations in APC occur rather late during the disease progression, whereas 
there are earlier mutations in p53 and K-ras. Recent data indicate that the intestinal 
microbiome and its interaction with a functionally impaired mucosal barrier may also 
play a role in CAC development. CACs frequently show aggressive growth and early 
metastases. The treatment of CAC in patients with colitis always includes 
proctocolectomy with ileoanal anastomosis as meta- or synchronic lesions are 
frequent.   
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Colorectal cancer in patients with chronic colitis: What is the risk? 
Ulcerative colitis (UC) is one of the two major forms of chronic inflammatory 
bowel diseases a relapsing inflammation of the colonic mucosa with variable 
extension from the rectum towards the cecum. The inflammation in ulcerative colitis 
is limited to the mucosal layer. It normally begins in the rectum where usually the 
highest activity of inflammation is found. In contrast, in Crohn’s disease, the second 
major form on inflammatory bowel disease, the inflammation is transmural affecting 
all layers of the gut wall. Involved gut segments show a discontinuous pattern 
frequently affecting the terminal ileum and also the colon. Both diseases usually 
occur in young adults between 20 and 30 years of age. However, disease onset may 
already be during childhood or be delayed to older ages. Due to the increasing 
incidence the number of young adults suffering from chronic colitis still is on the rise 
[1; 2; 3; 4; 5; 6; 7; 8]. 
The standard step-up treatment of UC starts with 5-aminosalicylic acid (which 
may have cancer-preventive activity). If the treatment response is not sufficient, 
steroids, immunosuppressants or biologicals (such as anti-TNF antibodies and in the 
near future anti-integrin antibodies) may be applied. Despite these treatment 
options there are patients that experience frequent flares of inflammation or 
develop a treatment resistant disease with chronic inflammatory activity. In those 
patients, when no complete remission (“mucosal healing”) can be achieved the 
continuous inflammation repeatedly destroys the epithelial surface of the mucosa. 
Crypt abscesses with crypt distortions are found and ongoing repair mechanisms are 
a histological hallmark. The loss of epithelial cells has to be compensated by 
increased epithelial proliferation as a repair mechanism which may finally be 
uncontrolled leading to CAC.  
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Subsequently, the risk of CAC is increased after long disease duration, 
especially in patients with chronic active disease [9; 10]. In older studies the risk for 
CAC in UC patients was reported to be around 7% at 20 years after onset of disease 
[11; 12; 13], 7-14% at 25 years [14; 15] and as high as 30% after 35 years [16] 
(Figure 1). This would mean that the life-time risk in any UC patient would be 2-4 
times the risk of the control population which is around 5% [10]. However, risk 
stratification seems to be possible with respect to specific characteristics of the 
disease. Eaden and co-workers published a meta-analysis on the risk of CAC in UC 
patients in 2001 based on 116 studies and on 54.478 patients. They confirmed that 
there is an increased risk for CAC in pancolitis as compared to left sided colitis [16] 
(Figure 1). The overall prevalence of CAC in any patient with UC was shown to be 
3.7%, in patients with pancolitis it was 5.4% [16]. In ulcerative proctitis the CAC 
risk appears not to be increased.  
More recent data indicate that the risk of CAC may be lower. Jess et al. used a 
population-based nationwide registry and did find no increase in the incidence of CRC 
in UC patients at all [17] (Figure 1). Neither the overall cancer risk nor the CAC risks 
were increased  after a median of 19 years of follow-up evaluation. This surprising 
finding, however, may be due to the higher rates of colectomy in UC patients in 
Denmark [17]. Using data from a large cohort of patients with extensive UC (600 
patients with 30 years of observation period) Rutter and co-workers reported 
cumulative incidences of CAC of 2.5% at 20 years of colitis duration, 7.6% at 30 
years, and 10.8% at 40 years [18] (Figure 1) indicating only a 1.5 to 2-fold increased 
risk for CRC as compared with the non-UC population. Only 30/600 patients (5%) 
developed CAC [18] in this cohort. A recent Swedish study including 7,607 patients 
with UC diagnosed between 1954 and 1989 analysed the frequency of CAC through 
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2004. The study indicates that over the past 35 years the risk of death from CAC 
declined markedly [19] (Table 1). A further recent study by Manninen et al. could 
confirm an only slightly increased risk for CAC in UC patients in a Finnish cohort [20]. 
The CAC risk was 3.09 (CI 1.50-5.75) for pancolitis and 3.62 (CI 2.00-11.87) for CD 
colitis [20]. However, 52% of the eleven detected CAC already were TNM stage 3 or 
4 [20]. Similar findings were obtained within the GETAID study [21] and in an 
Australian cohort [22].Recently Jess and co-workers performed a meta-analysis on 
population based studies [23]. They found that an average of 1.6% of patients with 
UC was diagnosed with CAC during 14 years of follow-up [23]. Men with UC had a 
greater risk of CAC as compared to women. In the population-based (unbiased and 
unselected cohorts) the diagnosis of UC increased the risk of CRC 2.4-fold as 
compared to the healthy population (which is clearly lower as compared to the Eaden 
data). A direct comparison of the Eaden- and Jess-data makes the differences 
obvious: In contrast to the above mentioned cumulative incidences of CAC of 2% at 
10 years and 8% at 20 years of follow-up for any patient with UC, these figures were 
only 0.4% and 1.1%–5.3%, respectively, in the recent meta-analysis [23] (Figure 1).  
The analysis on non-population based data derived from specialized centers 
may have introduced some selection-bias into the analyses. However, in a recent 
analysis of cases in the Swiss IBD cohort study which includes more than 50% of 
patients from specialized tertiary centers the rate of CAC was comparable to the low 
incidence reported in recent publications (own unpublished data). Thus the 
decreased incidence of CAC is more likely due to a better control of inflammation by 
improved medical therapy and higher rates of mucosal healing. However, evidence 
remains indirect. 
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Importantly, the risk to develop CAC is further increased in patients with 
primarily sclerosing cholangitis (PSC) [24; 25; 26; 27; 28; 29; 30; 31]. The 
mechanism behind that is unclear. Many hypotheses have been generated; however, 
none has been supported with sufficient clinical or experimental evidence. 
 
 
CRC in chronic colitis: What is the role of inflammation? 
In contrast to sporadic CRC the permanent stimulation of epithelial 
proliferation in an inflammatory environment is believed to play an important role for 
the pathogenesis of CAC in patients with chronic colitis [10; 20]. A typical adenoma-
carcinoma sequence is not found. UC patients may have low grade epithelial 
dysplasia in typical adenomatous lesions. However, dysplasia found in “dysplasia 
associated lesions or masses” (DALM) or in areas without any macroscopically visible 
mucosal alteration is believed to be the origin CAC  [32; 33; 34]. Such a lesion may 
require colectomy whereas low grade dysplasia in an ALM lesion (i.e. a typical 
adenoma) may be “treated as usual” [34; 35; 36; 37].  
An argument for the important role of inflammation for CAC development is 
the fact that CAC risk increases with the duration of the disease and correlates 
positively with the severity of inflammation and extend of the disease as mentioned 
above [10; 16; 20; 32; 38; 39] . Unfortunately, there is no uniform and general 
accepted definition of “disease-duration”. Onset of symptoms has generally been 
used as starting point for disease-duration in the studies that have identified this 
parameter as a risk factor [40]. Based on the meta-analysis by Eaden et al. it is 
assumed that the risk for CAC begins to increase 8 – 10 years after onset of 
inflammation [16]. This indicates that longer duration of inflammation promotes CAC 
8 
 
development. However, also very early CAC occurrence has been reported in some 
cases of colitis patients [41]. Persistent histological inflammation is a prerequisite for 
the development of CAC [10; 20; 32; 42]. As mentioned, the CAC risk is lower in left 
sided colitis and almost absent in proctitis – which in fact is somewhat surprising. 
The inflammation is most severe in the rectum and thus the highest levels of 
cytokines and ROS may be found there. Why this is not followed by a predominant 
localization of CACs in the rectum – even in proctitis – remains unclear. Even in 
patients with pancolitis most lesions have been reported to be left-sided [43; 44] – 
however, there are also reports on a random distribution over the whole colon [45]. 
Tthe crucial pathophysiological role of mucosal inflammation is highlighted by 
the fact that successful anti-inflammatory treatment (e.g. with 5-ASA or thiopurines) 
may reduce the risk to develop CAC [46; 47; 48; 49; 50; 51]. Whereas the benefit of 
anti-inflammatory treatment and subsequent mucosal healing overall is quite clear 
[52; 53], conflicting data have been obtained for single agents such as 5-ASA [54; 
55; 56; 57] .  
 
CRC in chronic colitis: Mutations and molecular mechanisms 
Pathogenetic features detected in patients with sporadic CRC such as 
chromosome instability, microsatellite instability, and DNA hypermethylation also can 
be found in patients with CAC [10; 45; 58; 59; 60; 61]. However, in contrast to 
patients with sporadic CRC cells of the inflamed mucosa-areas may harbour such 
changes before dysplasia or CAC can be detected [59,Li, 2012 #2919; 62]. 
Microsatellite instability, telomere shortening and chromosomal instability are 
regarded to occur as the molecular responses to genomic stress [62].  
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Inflammation alone may be sufficient to induce these changes. They may not 
necessarily lead to CAC making the early diagnosis of relevant early changes finally 
leading to CACvery difficult [63; 64; 65]. As mentioned above CAC does not show a 
typical adenoma-carcinoma sequence but may  develop from low-grade dysplasia to 
high-grade dysplasia and finally CAC  [66]. 
Inflammation is associated with the production of reactive oxygen species 
(ROS) which in turn may cause cellular damage that can become be oncogenic [67]. 
Thus, ROS production has been considered to be an important factor for the 
pathogenesis of chronic CAC [68; 69] (Figure 2). IBD has been discussed considered 
to be an “oxyradical overload” disease [70; 71; 72]. The deletion of ROS regulating 
genes such as the immediate early response gene X-1 (IEX-1) in a mouse model of 
colitis and colitis-associated cancer (azoxymethane/dextrane sodium sulfate 
[AOM/DSS] model) was followed by reduced inflammatory responses and CRC 
development [73]. However, with respect to the pathophysiological role of ROS the 
question arises why CAC does not always develop in the area of highest ROS 
production (i.e. in the rectum of patients with UC or in the terminal ileum in patient 
suffering from CD)   
Free radicals may either affect metabolic processes regulating DNA synthesis, 
RNA synthesis, protein assembly or DNA repair [71]. ROS may alter the function of 
genes and proteins that are crucial for the homeostasis of cell proliferation 
(necessary for tissue repair) and apoptosis (anoikis). When colonic epithelial cell lose 
their cell-cell of cell-matrix contacts they usually die from apoptosis/anoikis [74; 75]. 
For the closure of ulcers and epithelial defects in the colon of affected patients it may 
be important to avoid the inescapable induction of apoptosis, which consecutively 
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may in turn be associated with a lack of efficient control mechanisms for 
exaggerated cell proliferation. 
Similar to sporadic CRC colitis-associated high grade dysplasia or CAC develops 
with a sequence of molecular events on a cellular level; however, the sequence of 
events is different between sporadic CRC and CAC. High grade dysplasia and CAC 
development in patients with chronic colitis frequently occurs multifocally indicating 
that similar events take place in different areas of the affected mucosa [76; 77]. 
Similar to sporadic CRC in CAC chromosome instability and microsatellite instability 
occur in 85% and 15% of cases, respectively [78]. However, as mentioned the 
sequence of molecular events on the cellular levels differs between both entities. 
Whereas in sporadic CRC the loss of function of the adenomatous polyposis coli 
(APC) protein is an early event already occurring during the formation of early 
adenoma it is less frequent and occurs late in the pathogenesis of CAC [79; 80 
Umetani, 1999 #357] (Figure 2). As APC is essential for maintenance of mucosal and 
epithelial homeostasis an early loss of APC function may cause anoikis of epithelial 
cells thus preventing the development of CACs [81]. 
  p53-mutations, p53-loss of heterozygosity (LOH) or -loss of function are early 
and important events in the pathogenesis of CAC, whereas they occurs late in 
sporadic CRC (usually during transition from late adenoma to CRC) [82; 83; 84; 85; 
86] (Figure 2). Deletion of p53 is found in up to 85% of CACs [87; 88; 89]. p53 
mutations can be detected in chronically inflamed colon mucosa before any dysplasia 
develops (up to 50% of chronically inflamed patients) [84] (Figure 2). Mutant 
mutp53 prolongs TNF-alpha-induced NF-kappaB activation which in mice harboring a 
germline p53 mutation causes severe tissue damage and a higher risk to CAC [85]. 
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Mutated p53 caused a rapid development of high grade dysplasia, rapidly 
progressing to invasive carcinoma [85]  
DNA hypermethylation also is a typical feature of CAC [90]. Methylation of CpG 
islands in several genes can be found in chronically inflamed mucosa without visible 
dysplasia or lesion [61; 91]. Genes that are frequently hyper-methylated in chronic 
colitis-associated CRC are hMLH1 (in up to 46%, [92]), the cell cycle inhibitor 
p16INK4a and its promoter (up to 100%) [93] or p14ARF (33-60%, [94]). 
Another important factor in the pathogenesis of CAC is the intestinal 
microflora. In animal models of colitis the commensal flora or specific bacteria are 
necessary for the development of inflammation and for the induction of CAC [95; 
96]. Mice raised under germ-free conditions usually neither develop inflammation nor 
CAC. In IL-10 deficient animals the time point of occurrence of inflammation is 
dependent on the composition of the colonic microflora and CAC only develops in 
genetically identical mice in some animal facilities indicating the crucial influence of 
the microflora. 
In a recent study by the group of Jobin and co-workers the intestinal 
microbiota was identified as a target of inflammation that finally affects the initiation 
and progression of CAC. In interleukin (IL)-10–deficient mice a modification of the 
microbiome was found upon spontaneous development of colitis. Colonization of 
these mice with specific bacterial strains such as the commensal Escherichia coli 
NC101 supported the development of invasive inflammation induced CAC in 
azoxymethane (AOM)–treated IL-10 deficient mice [97; 98]. In addition, epithelial 
damage during inflammation and the translocation of bacteria across the epithelial 
barrier further may support CAC development. In a mouse model with defective 
intestinal barrier function at tumour sites the translocation of bacterial products was 
12 
 
followed by activation of myeloid cells, induction of IL‑23 and IL‑17 secretion and 
promotion of tumour growth [99]. IL-17 producing T-cells promote CAC 
tumorigenesis [99]. Further, IL-23 dependent signalling may promote CAC growth 
and progression [99]. In a mouse model of CAC IL-23 was mainly produced by 
tumour-associated myeloid cells which could be activated by microbial products in 
vivo again highlighting the potential role of the intestinal microbiota.  
 
Colorectal cancer in chronic colitis: What is the prognosis? 
Unfortunately CAC frequently is detected at late stages. Kavanagh and co-
workers found fifty percent (11/22) of UC patients and 71 % (5/7) of CD patients 
with CAC from a cohort of 2,843 inflammatory bowel disease patients had nodal or 
distant metastases at presentation [45]. Similar data have been reported from the 
Mayo Clinic [100]. CAC patients are younger, have more frequently multiple 
cancerous lesions, and higher proportions of mucinous or signet ring cell carcinomas 
[101]. In animal models of CAC cell growth is faster in inflamed areas [102]. This 
may contribute to the aggressiveness. The advanced stage at presentation causes 
less favourable outcome of CAC in IBD patients.  5-year survival rates for CAC ranges 
from 19–55% [45; 101; 103; 104; 105; 106]. The long term prognosis of CAC is 
even worse, when patients with the same tumour stage are compared: In a recent 
study stage III CAC patients had a poorer survival rate than patients with sporadic 
CRC (43.3% versus 57.4%, P = 0.0320) [101]. Encouragingly patients diagnosed at 
an early stage of CAC did not differ in their outcome from the sporadic CRC group 
[101]. This may underline the importance of surveillance colonoscopy for patients 
with chronic active colitis. Whereas this seems to be obvious the evidence is still 
weak [107]. The best performance of surveillance colonoscopy is discussed in many 
13 
 
guidelines and reviews and there is no space to do this here [35; 108; 109; 110; 
111; 112]. 
Surgical morbidity in patients with CAC is high despite the lower age at 
diagnosis as compared to sporadic CRC which may partially be caused by the 
underlying inflammatory disease [45]. 
 
As evidence is quite good that mucosal healing may prevent CAC development 
in chronic colitis patients this treatment goal is more and more adopted in clinical 
practice. Together with efficient surveillance strategies this seems to decrease the 
incidence of CAC in some countries [113]. Nevertheless it will be important to better 
understand the specific pathophysiology of these tumours to provide optimal 
targeted chemo-therapy for the patient group that will still develop CAC.  
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Figure legends 
 
Figure 1: Risk for CRC in UC patients with respect to disease duration. 
Comparisons of the meta-analyses/cohort studies by Eaden et al (6), Rutter et al (8) 
and Jess et al (10). There is a clear decrease of the risk evaluation between the 
studies. A trend for lower risk is observed in recent years. 
 
 
Figure 2: Pathways of CRC formation in sporadic cancer and chronic 
colitis associated cancer. The sequence of molecular events on the cellular levels 
differs. Whereas in sporadic CRC the loss of function of the adenomatous polyposis 
coli (APC) protein is an early event, it is less frequent and occurs late in the 
pathogenesis of chronic colitis-associated dysplasia and CRC. p53-mutations or loss 
of function are early events in chronic colitis associated CRC, whereas they occur late 
in sporadic CRC during transition from late adenoma to CRC.  
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Table 1: 
 
 10 years 20 years 30 years 
Pancolitis 1.5 3.8 7.6 
UC 1 2.3 5.2 
CD 0.5 1.4 2.2 
 
 
 
Table 1: Risk of colorectal cancer in 3 population based Swedish cohorts (1954 – 
1989) including 7 607 patients with IBD (198 227 patient-years). 196 CRCs were 
found in 188 patients. (Söderlund S, Brandt L, Lapidus A, Karlen P, Broström O, 
Löfberg O, Ekbom A, Askling J. Decreasing Time-Trends of Colorectal Cancer in a 
Large Cohort of Patients With lnflammatory Bowel Disease, Gastroenterology 
2009;136:1561-1567, Ref 9) 
 
 
 
 
 
